POTS Adrenergic Ab (CIHR Aims #1&2)
The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)
University of Calgary
125 participants
Jan 1, 2016
OBSERVATIONAL
Conditions
Summary
Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.
Eligibility
Inclusion Criteria5
- Patients who have been previously diagnosed with POTS
- Control subjects (patients not diagnosed with POTS)
- Age between 18 - 60 years
- Males and Females (Give that >80% of POTS patients are female, we will attempt to enroll a similar percentage of female control subjects)
- Able and willing to provide consent
Exclusion Criteria9
- Smokers
- Overt cause for postural tachycardia, i.e., acute dehydration
- Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing
- Highly trained athletes
- Subjects with somatization or severe anxiety symptoms will be excluded
- Use of drospirenone (a spironolactone analogue) containing oral contraceptive agent
- Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication
- Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
- Unable to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02673996